Alessia Fornoni

Novel Lipophagy Inducers as Potential Therapeutics for Lipid Metabolism Disorders

The paper identifies novel compounds that reduce lipid droplet accumulation in podocytes by inducing lipophagy, offering potential therapeutic benefits for lipid metabolism disorders.

FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes

This study shows that FGF21-FGFR4 signaling in cardiac myocytes causes concentric hypertrophy in diabetic mice, suggesting it may contribute to HFpEF and that FGFR4 blockade could be a therapeutic target.

Selective Modulator of Nuclear Receptor PPARy with Reduced Adipogenic Potential Ameliorates Experimental Nephrotic Syndrome

This study compares the effects of GQ-16, a PPARγ partial agonist, and pioglitazone, a PPARγ full agonist, in treating nephrotic syndrome in rats, finding that GQ-16 reduces proteinuria and co-morbidities with fewer adipogenic side effects.

Redefining Nephrotic Syndrome in Molecular Terms: Outcome-associated molecular clusters and patient stratification with noninvasive surrogate biomarkers

The paper identifies high-risk nephrotic syndrome patients through transcriptome analysis and develops non-invasive biomarkers to predict disease progression.

An eQTL landscape of kidney tissue in human nephrotic syndrome

The paper identifies eQTLs in glomerular and tubulointerstitial kidney tissues from nephrotic syndrome patients, finds tissue-specific eQTLs, and integrates them with a GWAS to identify associated genes.